Welcome to our dedicated page for FORE news (Ticker: FORE), a resource for investors and traders seeking the latest updates and insights on FORE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FORE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FORE's position in the market.
Foresight Acquisition Corp. announced the adjournment of its special meeting to approve a business combination with P3 Health Partners to December 3, 2021, at 7:00 a.m. Central Time. This is due to the need for additional time to file a proxy supplement, which will include revised pro forma financial statements. The adjournment does not affect the proposals to be voted on or the record date. Stockholders can change their redemption elections until 5:00 p.m. Eastern Time on December 1, 2021. The approval of the business combination will lead to its prompt closing, subject to conditions.
Foresight Acquisition Corp. (NASDAQ: FORE) has adjourned its Special Meeting for stockholders regarding the proposed business combination with P3 Health Partners to November 24, 2021, at 7:00 a.m. Central Time. The adjournment allows stockholders to further consider disclosures about changes in pro forma financial information following a decision to use purchase accounting instead of reverse recapitalization. No changes were made to the record date or proposals, and stockholders can adjust their redemption elections until November 22, 2021.
P3 Health Partners announced its acquisition of Medcore HP and Omni IPA Medical Group to expand into California’s Central Valley. The acquisition, pending regulatory approval, will enhance P3's capacity to take global risk on over 10,500 Medicare Advantage members. This strategic move provides access to a broader provider network, potentially increasing patient outreach and improving healthcare delivery in the region. P3 is also aiming to merge with Foresight Acquisition Corp (NASDAQ: FORE) to become a public company.
P3 Health Partners is set to merge with Foresight Acquisition Corp. (NASDAQ: FORE), allowing P3 to become a public company. This merger is planned to close soon, and P3 will host a Virtual Investor Day on November 11, 2021, to discuss growth strategies and financial results. The event will include a live Q&A session with management. Additionally, P3 will present at the Credit Suisse Healthcare Conference on November 8 and the BTIG Digital Health Forum on November 15, 2021. Stakeholders are encouraged to review the Proxy Statement for more details on the business combination.
Foresight Acquisition Corp. (NASDAQ: FORE) announced a special meeting for stockholders on November 18, 2021, at 9:00 a.m. Central Time, to approve a proposed business combination with P3 Health Partners. The definitive proxy statement was filed on October 28, 2021, with documents mailed to stockholders of record as of October 8, 2021. If approved, the business combination will result in the new company being named P3 Health Partners Inc. and listed as PIII on NASDAQ.
P3 Health Partners announced its upcoming participation in two virtual financial conferences in September 2021, following its business combination with Foresight Acquisition Corp. (NASDAQ:FORE). The 10th Annual Gateway Conference is set for September 9th at 11:30 AM ET, followed by the Wells Fargo Virtual Healthcare Conference on September 10th at 11:20 AM ET. This combination aims to enhance patient outcomes while lower costs through a physician-led approach. Investors are encouraged to review the preliminary proxy statement filed with the SEC regarding the merger.
P3 Health Partners has signed a definitive agreement with Foresight Acquisition Corp. (FORE) to go public, establishing an estimated enterprise value of $2.3 billion. The transaction includes a $200 million investment at $10 per share, led by Fidelity Management and Janus Henderson Investors. P3, focused on value-based care, aims to grow its Medicare Advantage operations significantly, targeting 35% patient growth annually. The business combination is expected to close in the second half of 2021, pending regulatory approvals.
Foresight Acquisition Corp. (Nasdaq: FOREU) announced that holders of its 31,625,000 units from the IPO on February 12, 2021, can separately trade Class A common stock and warrants starting April 5, 2021. Units not separated will continue to trade under FOREU, while separated shares will trade under symbols FORE and FOREWS. The Company aims to pursue business combinations primarily in technology-enabled consumer and consumer healthcare sectors. Cowen acted as the sole book-running manager for this offering.
